Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial

被引：7

作者：

Guttman-Yassky, E. ^{[1
,9
]}

Bahadori, L. ^{[2
]}

Brooks, L. ^{[3
]}

Clark, K. L. ^{[3
]}

Grindebacke, H. ^{[4
]}

Ho, C. N. ^{[5
]}

Katial, R. ^{[6
,7
]}

Pham, T. -H. ^{[8
]}

Walton, C. ^{[3
]}

Datto, C. J. ^{[2
]}

机构：

[1] Icahn Sch Med Mt Sinai, New York, NY USA

[2] AstraZeneca, Late Stage Dev Resp & Immunol, BioPharmaceut R&D, Gaithersburg, MD USA

[3] AstraZeneca, Late Stage Dev Resp & Immunol, BioPharmaceut R&D, Cambridge, England

[4] AstraZeneca, Late Stage Dev Resp & Immunol, BioPharmaceut R&D, Gothenburg, Sweden

[5] AstraZeneca, Patient Ctr Sci, BioPharmaceut Med, Gaithersburg, MD USA

[6] AstraZeneca, BioPharmaceut Med, Gaithersburg, MD USA

[7] Natl Jewish Hlth, Denver, CO USA

[8] AstraZeneca, Translat Sci & Expt Med, Early Resp & Immunol, BioPharmaceut R&D, Gaithersburg, MD USA

[9] Icahn Sch Med Mt Sinai, Kimberly & Er J Waldman Dept Dermatol, 1425 Madison Ave,Box 1047, New York, NY 10029 USA

来源：

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2023年 / 37卷 / 10期

关键词：

EFFICACY; SAFETY;

D O I：

10.1111/jdv.19195

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：E1211 / E1214

页数：4

共 50 条

[1] Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study
Bissonnette, R.
Haydey, R.
Rosoph, L. A.
Lynde, C. W.
Bukhalo, M.
Fowler, J. F.
Delorme, I.
Gagne-Henley, A.
Gooderham, M.
Poulin, Y.
Barber, K.
Jenkin, P.
Landells, I.
Pariser, D. M.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (03) : 403 - 410
[2] Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial
Merola, Joseph F.
Parish, Lawrence Charles
Guenther, Lyn
Lynde, Charles
Lacour, Jean -Philippe
Staubach, Petra
Cheng, Sue
Paris, Maria
Picard, Hernan
Deignan, Cynthia
Jardon, Shauna
Chen, Mindy
Papp, Kim A.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 90 (03) : 485 - 493
[3] Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): A randomized double-blind placebo-controlled trial
Tversky, Jody
Lane, Andrew P.
Azar, Antoine
CLINICAL AND EXPERIMENTAL ALLERGY, 2021, 51 (06) : 836 - 844
[4] Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial
Simpson, Eric L.
Silverberg, Jonathan I.
Worm, Margitta
Honari, Golara
Masuda, Koji
Sygu, Ewa
Schuttelaar, Marie L. A.
Mortensen, Eric
Laws, Elizabeth
Akinlade, Bolanle
Patel, Naimish
Maloney, Jennifer
Paleczny, Heather
Delevry, Dimittri
Xiao, Jing
Dubost-Brama, Ariane
Bansal, Ashish
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 90 (06) : 1190 - 1199
[5] An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study
Guttman-Yassky, Emma
Simpson, Eric L.
Reich, Kristian
Kabashima, Kenji
Igawa, Ken
Suzuki, Tetsuya
Mano, Hirotaka
Matsui, Takeshi
Esfandiari, Ehsanollah
Furue, Masutaka
LANCET, 2023, 401 (10372) : 204 - 214
[6] Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double-blind, placebo-controlled phase3trial
Cadot, Pierre
Hensel, Patrick
Bensignor, Emmanuel
Hadjaje, Celine
Marignac, Genevieve
Beco, Luc
Fontaine, Jacques
Jamet, Jean-Francois
Georgescu, Gabriela
Campbell, Karen
Cannon, Andrea
Osborn, Sarah C.
Messinger, Linda
Gogny-Goubert, Michel
Dubreuil, Patrice
Moussy, Alain
Hermine, Olivier
VETERINARY DERMATOLOGY, 2011, 22 (06) : 554 - 564
[7] Effects of abrocitinib on pruritus and eczema symptoms and tolerance in patients with moderate-to-severe atopic dermatitis in randomized, double-blind and placebo-controlled trials: A systematic review and a meta-analysis
Xie, Xingxing
Zhang, Jie
Huang, Fujing
Fan, Ling
BIOMEDICAL REPORTS, 2024, 20 (05)
[8] Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial
Guttman-Yassky, Emma
Thaci, Diamant
Pangan, Aileen L.
Hong, H. Chih-ho
Papp, Kim A.
Reich, Kristian
Beck, Lisa A.
Mohamed, Mohamed-Eslam F.
Othman, Ahmed A.
Anderson, Jaclyn K.
Gu, Yihua
Teixeira, Henrique D.
Silverberg, Jonathan I.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (03) : 877 - 884
[9] Efficacy and Safety of Intravenous Meloxicam in Patients With Moderate-to-Severe Pain Following Bunionectomy: A Randomized, Double-Blind, Placebo-controlled Trial
Pollak, Richard A.
Gottlieb, Ira J.
Hakakian, Fardin
Zimmerman, John C.
McCallum, Stewart W.
Mack, Randall J.
Keller, Rosemary
Freyer, Alex
Du, Wei
CLINICAL JOURNAL OF PAIN, 2018, 34 (10) : 918 - 926
[10] The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study
Bagel, Jerry
Duffin, Kristina Callis
Moore, Angela
Ferris, Laura K.
Siu, Kimberly
Steadman, Jennifer
Kianifard, Farid
Nyirady, Judit
Lebwohl, Mark
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 77 (04) : 667 - 674

← 1 2 3 4 5 →